Lois Anne Katz, M.D.

Effects of intensive blood-pressure control in type 2 diabetes mellitus
Cushman, William C; Evans, Gregory W; Byington, Robert P; Goff, David C Jr; Grimm, Richard H Jr; Cutler, Jeffrey A; Simons-Morton, Denise G; Basile, Jan N; Corson, Marshall A; Probstfield, Jeffrey L; Katz, Lois; Peterson, Kevin A; Friedewald, William T; Buse, John B; Bigger, J Thomas; Gerstein, Hertzel C; Ismail-Beigi, Faramarz
2010 Apr 29;362(17):1575-1585, New England journal of medicine
BACKGROUND: There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We investigated whether therapy targeting normal systolic pressure (i.e., <120 mm Hg) reduces major cardiovascular events in participants with type 2 diabetes at high risk for cardiovascular events. METHODS: A total of 4733 participants with type 2 diabetes were randomly assigned to intensive therapy, targeting a systolic pressure of less than 120 mm Hg, or standard therapy, targeting a systolic pressure of less than 140 mm Hg. The primary composite outcome was nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean follow-up was 4.7 years. RESULTS: After 1 year, the mean systolic blood pressure was 119.3 mm Hg in the intensive-therapy group and 133.5 mm Hg in the standard-therapy group. The annual rate of the primary outcome was 1.87% in the intensive-therapy group and 2.09% in the standard-therapy group (hazard ratio with intensive therapy, 0.88; 95% confidence interval [CI], 0.73 to 1.06; P=0.20). The annual rates of death from any cause were 1.28% and 1.19% in the two groups, respectively (hazard ratio, 1.07; 95% CI, 0.85 to 1.35; P=0.55). The annual rates of stroke, a prespecified secondary outcome, were 0.32% and 0.53% in the two groups, respectively (hazard ratio, 0.59; 95% CI, 0.39 to 0.89; P=0.01). Serious adverse events attributed to antihypertensive treatment occurred in 77 of the 2362 participants in the intensive-therapy group (3.3%) and 30 of the 2371 participants in the standard-therapy group (1.3%) (P<0.001). CONCLUSIONS: In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events. (ClinicalTrials.gov number, NCT00000620.)
— id: 126503, year: 2010, vol: 362, page: 1575, stat: Journal Article,

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Ismail-Beigi, Faramarz; Craven, Timothy; Banerji, Mary Ann; Basile, Jan; Calles, Jorge; Cohen, Robert M; Cuddihy, Robert; Cushman, William C; Genuth, Saul; Grimm, Richard H Jr; Hamilton, Bruce P; Hoogwerf, Byron; Karl, Diane; Katz, Lois; Krikorian, Armand; O'Connor, Patrick; Pop-Busui, Rodica; Schubart, Ulrich; Simmons, Debra; Taylor, Harris; Thomas, Abraham; Weiss, Daniel; Hramiak, Irene
2010 Aug 7;376(9739):419-430, Lancet
BACKGROUND: Hyperglycaemia is associated with increased risk of cardiovascular complications in people with type 2 diabetes. We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes. METHODS: ACCORD was a parallel-group, randomised trial done in 77 clinical sites in North America. People with diabetes, high HbA(1c) concentrations (>7.5%), and cardiovascular disease (or >or=2 cardiovascular risk factors) were randomly assigned by central randomisation to intensive (target haemoglobin A(1c) [HbA(1c)] of <6.0%) or standard (7.0-7.9%) glycaemic therapy. In this analysis, the prespecified composite outcomes were: dialysis or renal transplantation, high serum creatinine (>291.7 micromol/L), or retinal photocoagulation or vitrectomy (first composite outcome); or peripheral neuropathy plus the first composite outcome (second composite outcome). 13 prespecified secondary measures of kidney, eye, and peripheral nerve function were also assessed. Investigators and participants were aware of treatment group assignment. Analysis was done for all patients who were assessed for microvascular outcomes, on the basis of treatment assignment, irrespective of treatments received or compliance to therapies. ACCORD is registered with ClinicalTrials.gov, number NCT00000620. FINDINGS: 10 251 patients were randomly assigned, 5128 to the intensive glycaemia control group and 5123 to standard group. Intensive therapy was stopped before study end because of higher mortality in that group, and patients were transitioned to standard therapy. At transition, the first composite outcome was recorded in 443 of 5107 patients in the intensive group versus 444 of 5108 in the standard group (HR 1.00, 95% CI 0.88-1.14; p=1.00), and the second composite outcome was noted in 1591 of 5107 versus 1659 of 5108 (0.96, 0.89-1.02; p=0.19). Results were similar at study end (first composite outcome 556 of 5119 vs 586 of 5115 [HR 0.95, 95% CI 0.85-1.07, p=0.42]; and second 1956 of 5119 vs 2046 of 5115, respectively [0.95, 0.89-1.01, p=0.12]). Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy. Seven secondary measures at study end favoured intensive therapy (p<0.05). INTERPRETATION: Microvascular benefits of intensive therapy should be weighed against the increase in total and cardiovascular disease-related mortality, increased weight gain, and high risk for severe hypoglycaemia. FUNDING: US National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; National Eye Institute; Centers for Disease Control and Prevention; and General Clinical Research Centers
— id: 126502, year: 2010, vol: 376, page: 419, stat: Journal Article,

National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics
Furmaga, Elaine M; Cunningham, Francesca E; Cushman, William C; Dong, Diane; Jiang, Rong; Basile, Jan; Katz, Lois A; Rutan, Gale H; Berlowitz, Dan R; Papademetriou, Vasilios; Glassman, Peter A
2008 Oct;10(10):770-778, Journal of clinical hypertension
The authors sought to determine the prescribing practices of clinicians treating veterans with hypertension. A descriptive analysis was performed using a national pharmacy database of patients with a diagnosis of hypertension receiving antihypertensive medication in the fiscal years 2000 to 2006. Angiotensin-converting enzyme inhibitors were the most frequently prescribed antihypertensive class, with utilization increasing from 56.0% in fiscal year 2000 to 63.2% of patients in 2006. Utilization of thiazide-type diuretics increased from 31.9% of patients in fiscal year 2000 to 42.0% in 2006. When patient comorbidities were taken into consideration, 48.1% of patients defined as having uncomplicated hypertension had at least one prescription for a thiazide diuretic in fiscal year 2006. Utilization by monotherapy and combination therapy were also evaluated. The trends in utilization allowed for identification of areas in which a change in prescribing practices may improve blood pressure control and health outcomes in the Veterans Health Administration
— id: 126504, year: 2008, vol: 10, page: 770, stat: Journal Article,

Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design
Sullivan, Mark D; Anderson, Roger T; Aron, David; Atkinson, Hal H; Bastien, Arnaud; Chen, G John; Feeney, Patricia; Gafni, Amiram; Hwang, Wenke; Katz, Lois A; Narayan, K M; Nwachuku, Chuke; O'Connor, Patrick J; Zhang, Ping
2007 Jun 18;99(12A):90i-102i, American journal of cardiology
Diabetes mellitus affects not only life expectancy but also quality of life. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial's health-related quality of life (HRQOL) and cost-effectiveness components will enable the assessment of the relative importance of the various outcomes from the point of view of patients, provide an understanding of the balance between the burdens and benefits of the intervention strategies, and offer valuable insights into adherence. The HRQOL measures used include the Diabetes Symptoms Distress Checklist; the 36-Item Short Form Health Survey, Version 2 (SF-36) (RAND Corporation, Santa Monica, CA); the Patient Health Questionnaire (PHQ) depression measure (Pfizer Inc, New York, NY); the World Health Organization (WHO) Diabetes Treatment Satisfaction Questionnaire (DTSQ); and the EuroQol Feeling Thermometer (EuroQol Group, Rotterdam, Netherlands). The cost-effectiveness analysis (CEA) in ACCORD will provide information about the relative economic efficiency of the different interventions being compared in the trial. Effectiveness will be measured in terms of cardiovascular event-free years gained and quality-adjusted life-years gained (using the Health Utilities Index Mark 3 [HUI-3] [Health Utilities Inc., Dundas, Ontario, Canada] to measure health-state utility). Costs will be direct medical costs assessed from the perspective of a single-payer health system collected by means of patient and clinic cost forms and hospital discharge summaries. The primary HRQOL and CEA hypotheses mirror those in the main ACCORD trial, addressing the effects of the 3 main ACCORD interventions considered separately. There are also secondary (pairwise reference case) comparisons that do not assume independence of treatment effects on HRQOL. CEA will be done on a subsample of 4,311 ACCORD participants and HRQOL on a subsample of 2,053 nested within the CEA subsample. Most assessments will occur through questionnaires at baseline and at 12, 36, and 48 months
— id: 126505, year: 2007, vol: 99, page: 90i, stat: Journal Article,

Nanophthalmia and chronic angle-closure glaucoma
Burgoyne, Claude; Tello, Celso; Katz, L Jay
2002 Dec;11(6):525-528, Journal of glaucoma
— id: 148675, year: 2002, vol: 11, page: 525, stat: Journal Article,

Comparison of intradermal and intramuscular vaccination for hepatitis B in dialysis patients
Lazowski, P; Katz, LA; Simberkoff, MS; Goldfarb, DS
1996 SEP ;7(9):A1201-A1201, Journal of the American Society of Nephrology
— id: 52798, year: 1996, vol: 7, page: A1201, stat: Journal Article,

Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects
Ahmad S; Robertson HT; Golper TA; Wolfson M; Kurtin P; Katz LA; Hirschberg R; Nicora R; Ashbrook DW; Kopple JD
1990 Nov;38(5):912-918, Kidney international
Since carnitine deficiency has been reported in some patients undergoing maintenance hemodialysis, we studied the effects of intravenous infusion of L-carnitine or placebo at the end of each dialysis treatment. The trial, which lasted seven months (one month baseline, 6 months treatment) was multicenter, double blind, placebo controlled, and randomized. Eighty-two long-term hemodialysis patients, who were given either carnitine (N = 38) or placebo (N = 44), completed this study. In each group, clinical and biochemical parameters during treatment were compared with baseline values. Intra-dialytic hypotension and muscle cramps were reduced only in the carnitine treated group, while improvement in post-dialysis asthenia was noticed in both carnitine and placebo groups. Maximal oxygen consumption, measured during a progressive work exercise test, improved significantly in the carnitine group (111 +/- 50 ml/min. P less than 0.03) and was unchanged in the placebo group. L-carnitine treatment was associated with a significant drop in pre-dialysis concentrations of serum urea nitrogen, creatinine and phosphorus (means +/- SEM, 101 +/- 4.5 to 84 +/- 3.9, 16.7 +/- 0.67 to 14.7 +/- 0.64, and 6.4 +/- 0.3 to 5.5 +/- 0.4 mg/dl, respectively, P less than 0.004). No significant changes in any of these variables were noticed in the placebo group. Mid-arm circumference and triceps skinfold thickness were measured in 11 carnitine and 13 placebo treated patients. Calculated mid-arm muscle area increased in the carnitine patients (41.37 +/- 2.68 to 45.6 +/- 2.82 cm2, P = 0.05) and remained unchanged in the placebo patients.(ABSTRACT TRUNCATED AT 250 WORDS)
— id: 57461, year: 1990, vol: 38, page: 912, stat: Journal Article,

EXCELLENT DIALYSIS TOLERANCE IN HIV-POSITIVE PATIENTS WITHOUT AIDS
KATZ, LA
1990 JAN ;37(1):330-330, Kidney international
— id: 51514, year: 1990, vol: 37, page: 330, stat: Journal Article,

Treating black hypertensives with capozide
Katz LA; Cobbol C
1988 Jul;1(3 Pt 3):224S-226S, American journal of hypertension
Twenty-four black men with mild to moderate essential hypertension were enrolled in an open-label trial comparing the efficacy of two doses of Capozide (captopril and hydrochlorothiazide). All antihypertensive drugs were discontinued and patients then received placebo for 2 weeks. Twenty-two patients, mean age 59.1 +/- 14.3 years, with sitting diastolic blood pressure (BP) 92 to 110 mm Hg, entered the 6-week active-drug phase. Eleven patients (Group A) were randomized to Capozide 25/15 and 11 (Group B) to Capozide 50/15. Baseline mean BPs were 151.0/100.7 mm Hg in Group A and 153.1/100.7 mm Hg in Group B. At week 6, mean BPs were 128.7/84.4 mm Hg in Group A and 126.8/82.7 mm Hg in Group B. Uric acid, blood urea nitrogen and creatinine levels rose slightly in both groups. There were no adverse events. Eighteen patients had normal BPs at study completion. Twice-daily Capozide treatment is effective and well tolerated in blacks; patients responded equally well to both doses
— id: 8290, year: 1988, vol: 1, page: 224S, stat: Journal Article,

HERPES-ZOSTER IN DIALYSIS PATIENTS
KATZ, LA
1988 JAN ;33(1):227-227, Kidney international
— id: 41835, year: 1988, vol: 33, page: 227, stat: Journal Article,

Olfaction and hemodialysis: baseline and acute treatment decrements
Conrad P; Corwin J; Katz L; Serby M; LeFavour G; Rotrosen J
1987 ;47(2):115-118, Nephron
The effect of hemodialysis (HD) on olfactory recognition and memory function was investigated in people receiving chronic HD treatment. Fifteen subjects were given an olfactory recognition task 0.5 h before and 0.5 h after a dialysis session in counterbalanced order. Ten dialysis patients received a verbal recall task twice. Ten age-matched normal subjects received the olfactory task twice. Results were: (1) olfactory scores in the HD group were significantly lower than control subjects scores; (2) within the dialysis sample, olfactory identification scores were significantly lower after treatment than before, and (3) there were no parallel decreases in memory performance of the dialysis group after a HD treatment. We therefore conclude that those subjects receiving HD treatment demonstrate acute and chronic deficits in olfactory recognition which are unlikely to be due to fatigue, cognitive disequilibrium, anticoagulant treatment or high levels of uremic toxins
— id: 23613, year: 1987, vol: 47, page: 115, stat: Journal Article,

RENAL AMYLOIDOSIS IN SUBCUTANEOUS HEROIN ABUSERS
Gallo, GR; Neugarten, J; Buxbaum, J; Katz, LA; Rubinstein, J; Baldwin, DS
1986 Jan;29(1):187-187, Kidney international
— id: 31092, year: 1986, vol: 29, page: 187, stat: Journal Article,

CAPTOPRIL FOR GERIATRIC HYPERTENSIVES
Katz, LA
1986 Jan;29(1):249-249, Kidney international
— id: 31094, year: 1986, vol: 29, page: 249, stat: Journal Article,

CAPTOPRIL FOR GERIATRIC HYPERTENSIVES
Katz, LA
1986 Dec;4(4):S426-S428, Journal of hypertension
— id: 31333, year: 1986, vol: 4, page: S426, stat: Journal Article,

Amyloidosis in subcutaneous heroin abusers ("skin poppers' amyloidosis")
Neugarten J; Gallo GR; Buxbaum J; Katz LA; Rubenstein J; Baldwin DS
1986 Oct;81(4):635-640, American journal of medicine
Systemic amyloidosis has recently emerged as a major cause of nephropathy among heroin abusers in New York City. Although focal glomerulosclerosis is typically seen in intravenous drug abusers who present with the nephrotic syndrome, those who escape this complication are at risk for the later development of amyloidosis related to their use of the subcutaneous route. Twenty such addicts identified between 1981 and 1984 are described. Patients typically present with chronic suppurative skin infections, edema, the nephrotic syndrome, benign urinary sediment, and normal-sized or enlarged kidneys. Tubular dysfunction, particularly renal tubular acidosis and diabetes insipidus, is frequent. Progression of renal insufficiency is characteristically rapid. Prolonged survival of heroin abusers and exhaustion of intravenous access requiring recourse to the subcutaneous route underlie the occurrence of amyloidosis in the addict population. Chronic suppurative skin infection consequent to repeated subcutaneous injection appears to be the underlying cause
— id: 59943, year: 1986, vol: 81, page: 635, stat: Journal Article,

AMYLOID-A PROTEIN-RELATED RENAL AMYLOIDOSIS IN DRUG-ABUSERS
Rubenstein, J; Emancipator, SN; Katz, LA; Feiner, H; Gallo, GR
1982 ;21(1):212-212, Kidney international
— id: 30497, year: 1982, vol: 21, page: 212, stat: Journal Article,

Acquired cystic disease of kidney in chronic dialysis patients
Feiner HD; Katz LA; Gallo GR
1981 Mar;17(3):260-264, Urology
Eight cases of acquired cystic disease of the kidney (ACDK) associated with chronic renal failure and hemodialysis are described. No patient had a family history or clinical evidence of congenital adult polycystic kidney disease (CAPKD). Glomerulonephritis was the cause of renal failure in 6, and pyelonephritis in 2. Massive renal and perirenal hemorrhage necessitated 3 nephrectomies in 2 patients. Single kidney weights did not exceed 280 Gm., a major feature in the distinction of ACDK from CAPKD. Morphologically, in addition to the usual stigmata of end-stage kidneys, 40 to 80 per cent of the renal parenchyma was replaced by small cysts. Continuity of cysts with tubules was established by nephron dissection
— id: 59972, year: 1981, vol: 17, page: 260, stat: Journal Article,

AMBULATORY BLOOD-PRESSURE MONITORING IN HEMODIALYSIS-PATIENTS
Katz, LA; Greenblatt, HA; Dixon, JD; Rubler, S
1981 ;19(1):151-151, Kidney international
— id: 30287, year: 1981, vol: 19, page: 151, stat: Journal Article,

Nodular glomerulopathy associated with nonamyloidotic kappa light chain deposits and excess immunoglobulin light chain synthesis
Gallo GR; Feiner HD; Katz LA; Feldman GM; Correa EB; Chuba JV; Buxbaum JN
1980 Jul;99(3):621-644, American journal of pathology
A nodular glomerulopathy characterized by mesangial deposits of monoclonal kappa light chains was detected by immunofluorescence in a renal biopsy from a patient with proteinuria and hypertension. These nodules lacked the tinctorial and morphologic features of amyloid. Ultrastructurally, the nodules contained electron-dense granular deposits as well as fibrils in parallel arrangement. The fibrils measured 110-140 A in diameter. They were consistent in size with amyloid fibrils. However, they differed in lacking the randomly oriented network of typical amyloid fibrils and more closely resembled fibrils intrinsic to mesangial matrix. The patient had no bone marrow or X-ray evidence of myeloma and no evidence of free monoclonal light chains in serum or concentrated urines. Biosynthetic studies of the patient's bone marrow cells demonstrated unbalanced immunoglobulin synthesis with excess production of monoclonal kappa light chains. These observations suggest that the observed glomerulopathy results from direct deposition of monoclonal light chains. Deposits with kappa light chain determinants have been found in 7 other patients with similar nodular glomerulopathies, 4 of whom had diagnosed clinical myeloma. The lesion of nonamyloidotic nodular glomerulopathy previously described in 19 patients, nor examined by immunopathologic techniques or not shown to contain light chain determinants, may have a similar pathogenesis
— id: 45921, year: 1980, vol: 99, page: 621, stat: Journal Article,

Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients
Katz LA; Simberkoff MS; Schiffman G; Spicehandler JR; Moldover NH; Rahal JJ Jr
1980 ;26(3):369-371, Transactions (American Society for Artificial Internal Organs)
— id: 38217, year: 1980, vol: 26, page: 369, stat: Journal Article,

Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients
Simberkoff MS; Schiffman G; Katz LA; Spicehandler JR; Moldover NH; Rahal JJ Jr
1980 Aug;96(2):363-370, Journal of laboratory & clinical medicine
PCP vaccine was administered to 21 adult hemodialysis patients and 25 control patients with no renal nor hepatic dysfunction. Antibody concentrations measured by the RIA technique were lower in the hemodialysis than in the control patients in both prevaccination sera and specimens obtained 3 to 4 weeks following vaccination. However, 6 months after vaccination, RIA GMACs in hemodialysis and control subjects were more nearly alike. OTs against Streptococcus pneumoniae, types 1 and 3, were measured in paired sera from vaccine recipients. Opsonic activity against S. pneumoniae, type I, was detected as frequently in the 3 to 4 week postvaccine sera of the dialysis as in those of control patients. However, there was a poor correlation between OTs and RIA-ACs against this organism. There was good correlation between OT and RIA-AC against type 3 pneumococci in 3 to 4 week postvaccine sera, and significantly more control patients had opsonic activity detectable in these specimens. No clinical S. pneumoniae infections have been observed in vaccine recipients. However, continued follow-up will be necessary to document the degree to which hemodialysis patients are protected by pneumococcal vaccines and the relationship between protection and antibody concentration or OTs
— id: 38215, year: 1980, vol: 96, page: 363, stat: Journal Article,

RADIOIMMUNO AND OPSONIC ANTIBODY-RESPONSES TO PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE IN HIGH-RISK PATIENTS WITH CHRONIC RENAL OR HEPATIC-DISEASE
Simberkoff, MS; Schiffman, G; Katz, LA; Moldover, NH; Rahal, JJ
1980 ;28(2):A514-A514, Clinical research
— id: 28119, year: 1980, vol: 28, page: A514, stat: Journal Article,

ACQUIRED CYSTIC-DISEASE OF THE KIDNEY (ACKD) COMPLICATING CHRONIC RENAL-FAILURE AND HEMODIALYSIS
Feiner, H; Katz, L; Gallo, G
1979 ;40(Suppl 1):253-254, Laboratory investigation
— id: 30029, year: 1979, vol: 40, page: 253, stat: Journal Article,

NON-AMYLOIDOTIC LIGHT CHAIN GLOMERULOPATHY ASSOCIATED WITH UN- BALANCED IMMUNOGLOBULIN-SYNTHESIS
Gallo, GR; Feiner, HD; Katz, LA; Buxbaum, J
1979 ;16(6):929-929, Kidney international
— id: 30065, year: 1979, vol: 16, page: 929, stat: Journal Article,

STRESS-TESTING WITH THALLIUM 201 IMAGING TO DETECT LATENT CORONARY-DISEASE IN HEMODIALYSIS-PATIENTS
Katz, LA; Fisher, VJ; Salik, JM; Agatson, A; Rubler, S
1979 ;16(6):890-890, Kidney international
— id: 29994, year: 1979, vol: 16, page: 890, stat: Journal Article,

STRESS-TESTING WITH TL-201 IMAGING TO DETECT LATENT CORONARY- DISEASE IN HEMODIALYSIS-PATIENTS
Katz, LA; Fisher, VJ; Salik, JM; Agatson, A; Rubler, S
1979 ;27(2):A419-A419, Clinical research
— id: 30015, year: 1979, vol: 27, page: A419, stat: Journal Article,

ACQUIRED CYSTIC-DISEASE OF THE KIDNEY (ACKD) COMPLICATING CHRONIC RENAL-FAILURE AND HEMODIALYSIS
Feiner, H; Katz, L; Gallo, G
1978 ;14(6):710-710, Kidney international
— id: 30057, year: 1978, vol: 14, page: 710, stat: Journal Article,

EXPERIENCE WITH A NEW ORAL DIURETIC RO 10-6338 IN PATIENTS WITH CONGESTIVE HEART-FAILURE
GELFAND, ML; GOODKIN, L; KATZ, L
1977 ;25(3):A549-A549, Clinical research
— id: 39984, year: 1977, vol: 25, page: A549, stat: Journal Article,

MINOXIDIL - 3 YEARS OF CLINICAL EXPERIENCE
Katz, LA; Rosenthal, R
1977 ;12(6):501-501, Kidney international
— id: 29962, year: 1977, vol: 12, page: 501, stat: Journal Article,

SPONTANEOUS RENAL HEMORRHAGE WITH RETROPERITONEAL HEMATOMA IN 2 DIALYZED PATIENTS
Katz, LA; Nidus, BD; Otrakji, J
1976 ;10(6):519-519, Kidney international
— id: 29644, year: 1976, vol: 10, page: 519, stat: Journal Article,

RED-CELL MICROCYTOSIS ASSOCIATED WITH DIALYSIS DEMENTIA
Nidus, BD; Otrakji, J; Katz, LA; Sassa, S
1976 ;10(6):522-522, Kidney international
— id: 29645, year: 1976, vol: 10, page: 522, stat: Journal Article,

CHRONIC HEMODIALYSIS WITHOUT A FISTULA OR SHUNT
NIDUS, B; NEELAKANTAPPA, K; MATALON, R; KATZ, L; NEHEMIAH, P; ZERBINO, V
1975 ;8(6):431-431, Kidney international
— id: 49793, year: 1975, vol: 8, page: 431, stat: Journal Article,

Glomerular sclerosis in adults with nephrotic syndrome
Matalon, R; Katz, L; Gallo, G; Waldo, E; Cabaluna, C; Eisinger, R P
1974 Apr;80(4):488-495, Annals of internal medicine
— id: 76974, year: 1974, vol: 80, page: 488, stat: Journal Article,

Hemodialysis using femoral vessel cannulation
Nidus BD; Matalon R; Katz LA; Cabaluna C; Tan C; Eisinger RP
1974 ;13(5):416-420, Nephron
— id: 28284, year: 1974, vol: 13, page: 416, stat: Journal Article,

Tuberculosis in dialyzed patients
Pradhan RP; Katz LA; Nidus BD; Matalon R; Eisinger RP
1974 Aug 12;229(7):798-800, JAMA
— id: 28283, year: 1974, vol: 229, page: 798, stat: Journal Article,

A 6 year clinical experience with arteriovenous fistulas and bypass for hemodialysis
Zerbino VR; Tice DA; Katz LA; Nidus BD
1974 Dec;76(6):1018-1023, Surgery
— id: 28282, year: 1974, vol: 76, page: 1018, stat: Journal Article,

The use of gentamicin in peritoneal dialysis. II. Microbiologic and clinical results
Hyams, P J; Smithivas, T; Matalon, R; Katz, L; Simberkoff, M S; Rahal, J J Jr
1971 Dec;124(6):Suppl 124:84-Suppl 124:89, Journal of infectious diseases
— id: 38264, year: 1971, vol: 124, page: Suppl 124:84, stat: Journal Article,

Functional aortic insufficiency. A feature of renal failure
Matalon, R; Moussalli, A R; Nidus, B D; Katz, L A; Eisinger, R P
1971 Dec 30;285(27):1522-1523, New England journal of medicine
— id: 28286, year: 1971, vol: 285, page: 1522, stat: Journal Article,